BridgeBio Pharma, Inc.
About BridgeBio Pharma, Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $502.1M
- Net income
- -$69.0K
- Total assets
- $936.0M
- Market cap
- $13.2B
- Gross margin
- 95.8%
- Operating margin
- -104.2%
- Net margin
- -146.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $502.1M
- Cost of revenue
- $21.0M
- Gross profit
- $481.1M
- Operating expenses
- $1.0B
- Operating income
- -$523.4M
- Income tax
- $435.0K
- Net income
- -$732.9M
- EPS (basic)
- $-3.78
- EPS (diluted)
- $-3.78
Balance sheet
- Total assets
- $936.0M
- Current assets
- $797.7M
- Total liabilities
- $3.0B
- Current liabilities
- $288.0M
- Shareholders’ equity
- -$2.1B
Cash flow
- Operating cash flow
- -$445.9M
- Investing cash flow
- -$24.5M
- Financing cash flow
- $359.3M
- Net cash flow
- -$111.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.2B
- EPS (diluted)
- $-3.78
- Shares outstanding
- 196.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 27, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $69.0K in FY2025.
- Revenue grew 620% from FY2021 to FY2025.
- Gross margin of 95.8%, net margin -146.0%.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BridgeBio Pharma, Inc..
Write a review
News about BridgeBio Pharma, Inc.
News & sentiment via Polygon.io
